GATC Health Showcases Regulatory Innovation using Advanced AI at BIO International Convention

Irvine, CA—June 26, 2025— GATC Health, a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery and development, announced the successful participation of its executive team at the recent BIO International Convention, the world’s premier biotechnology event.

Dr. Rahul Gupta, President of GATC Health, participated as a featured panelist on the session titled “AI in Regulatory Decision-Making: Navigating the New FDA Roadmap.” He was joined on the panel by senior policy leaders from OpenAI, Sanofi, Pi Health, and Baker McKenzie. Dr. Gupta shared his expertise on the evolving regulatory environment for artificial intelligence in biotech, with a particular focus on the FDA’s newly announced roadmap for integrating AI into regulatory decision-making.

“The BIO International Convention was an outstanding opportunity to engage with leaders across the biotech industry,” noted Dr. Gupta. “It was the perfect platform to share GATC’s vision for an AI-enabled regulatory process that speeds and focuses decision making. There is significant interest in our AI as an independent tool to more accurately predict clinical outcomes, and it’s clear that the industry is ready to embrace new approaches that accelerate drug discovery while improving safety and outcomes. We look forward to building on this momentum and partnering with innovators who share our vision for the future of healthcare.”

The recent FDA roadmap marks a significant shift toward using advanced, human-relevant technologies—especially AI-powered tools—to improve drug safety prediction and regulatory processes. This strategy aims to reduce reliance on animal testing and accelerate the adoption of New Approach Methodologies (NAMs), including computer modeling and virtual simulations of human biology. The FDA’s plan includes expanding regulatory acceptance of AI-enabled models, revising guidance, and collaborating with federal partners to validate these tools, all in alignment with the FDA Modernization Act 2.0. The agency is targeting a three- to five-year implementation timeline to make AI-driven approaches central to drug development and review.

Tyrone Lam, Chief Business Officer of GATC Health, also attended the convention, meeting with potential biotech executives and investment firms to explore new partnerships and opportunities. His outreach furthered GATC’s mission to expand the impact of its multiomics and AI-powered solutions to better inform decision-making across the life sciences sector.

GATC Health’s active participation at BIO underscores its commitment to advancing regulatory science and accelerating the discovery and development of safer, more effective therapies through artificial intelligence.

About GATC Health Corp

GATC Health Corp. is a technology company that is transforming drug discovery and development through its AI-driven platform and approach. The company’s validated and proprietary Multiomics Advanced Technology™ (“MAT”) simulates human biochemistry’s billions of interactions to rapidly create novel therapeutics, identify and confirm targets, accelerate development, and derisk drug pipelines by predicting efficacy, safety, and off-target effects. Founded in 2020, GATC Health is headquartered in Irvine, CA, and has facilities in Utah, West Virginia and Washington DC. For more information, visit gatchealth.com.